Nigel Talboys is has global responsibility for Government Affairs and Public Policy for Terumo Blood and Cell Technologies, where he is responsible for analysing legislation to determine its impact on the organization and building relationships with governments, trade associations, non-government organizations and patient associations to advance the medical technology industry.
He has wide experience in the Medical Technology field and has worked for several multinational companies in a variety of business functions prior to joining Terumo. These companies include Becton Dickinson and C.R. Bard. During his time at Becton Dickinson he was involved in the development of new techniques used in regional anaesthesia, particularly in the development of Combined Spinal and Epidural Anaesthesia. At C.R. Bard he developed a new business model in Europe used to treat prostate cancer with brachytherapy. He has also been involved in several acquisitions and integration projects. He is President of the Blood Transfusion Association (BTA), Chairperson of the Public Affairs Group for the Association of British HealthTech Industries (ABHI), Chairperson of the Regulatory Group and board member for MedPharmPlast Europe and a board member of the UK / Japan 21 st Century Group. The UK/Japan 21 Century Group’s primary goal is to serve as a catalyst for increasing the level of mutual understanding and awareness of the political, economic, and social environments in each country. Following each of the group’s annual meeting, a summary report and recommendations are submitted to the prime ministers of both countries.
A British national, Nigel has spent the last 30 years working outside his home country in France, German and now Belgium. He studied Human Biology at Loughborough University in England and attended an Executive Business Program at Harvard University in Boston, USA.